The global angina pectoris drugs market size is expected to expand at a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increased expenditure in healthcare, availability of drugs treatment, and rising number of targeted population.
Angina pectoris drugs are used to treat the angina pectoris condition, which is normally occurred due to reduced blood flow to the heart muscle. Some key symptoms of this condition include pain in the body especially discomfort in chest, back, neck, and shoulders. This health condition is expected to occur due to angioplasty, drugs, artery bypass surgery, and lifestyle changes while it can be categorized as microvascular, prinzmetal, stable, and unstable variant. It majorly impact on quality of life, ability to work, and costs to the society.
Prevalence of chronic stable angina pectoris is expected to be 2-4% in the seven key markets namely Japan, Germany, the U.S., Italy, Spain, the U.K., and France. Over 8 million men and women in the U.S. are suffering from chronic angina pectoris, as per a latest report by Heart Disease and Stroke Statistics from the American Heart Association. The incidences of angina increases in both genders with age, ranging from 2-4% in men aged 65-74 and 0.1-1% in women aged 45-54.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing demand for targeted treatments, available effective treatment method, and increased expenditure on healthcare globally are expected to drive the market growth.
- Increasing geriatric population in countries such as developed countries such as the US and the UK are expected to influence the demand for angina pectoris drugs in the coming years.
- Favorable government policies across the globe for adoption and approval of clinical trials of advanced therapy medicinal products are expected to boost the market.
- Continuously expansion in the activities such as investments for innovative products and collaborations is expected to fuel the market growth.
- Declining of branded sales of the drugs due to condition of a larger portion of prescriptions is a key challenge expected to restrain the market growth.
Scope of the Report
The report on the global angina pectoris drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | Angina Pectoris Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
| Base Year | 2020 |
| Historic Data | 2018–2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Therapeutic Classes (Anti-Platelets, Calcium Antagonists, Anticoagulants, Beta Blockers, and Others [Nitrates, Anti-anginal, and ACE inhibitors]) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
| Key Players Covered in the Report | SANOFI-Synthelabo (India) Private Limited.; Gilead Sciences, Inc.; Amgen, Inc.; GlaxoSmithKline Plc.; AstraZeneca Plc.; Eli Lilly and Company; Pfizer, Inc.; Novartis International AG; XyloCor Therapeutics, Inc.; and Tasly Pharmaceuticals, Inc. |
Market Segment Insights
Beta blockers segment is expected to grow at a rapid pace
Based on therapeutic classes, the global angina pectoris drugs market is divided into anti-platelets, calcium antagonists, anticoagulants, beta blockers, and others. The other segment is further divided into nitrates, anti-anginal, and ace inhibitors. The beta blockers segment is expected to grow at a rapid pace in the coming years owing to rising adoption of therapeutic methods among the patients of angina pectoris. However, the others segment is attributed to account for a key market share during the forecast period due to advancement in technology and various research and development initiatives by several governments.
North America is anticipated to constitute a key market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to constitute a key share of the market in the coming years owing to the presence of major market players and rising adoption of therapeutics in the region. Meanwhile, the market of Asia Pacific is projected to exhibit a substantial growth rate during the forecast period due to the large population and unmet medical needs in the region.
Segments
Segments Covered in the Report
The global angina pectoris drugs market has been segmented on the basis of
Therapeutic Classes
- Anti-Platelets
- Calcium Antagonists
- Anticoagulants
- Beta Blockers
- Others
- Nitrates
- Anti-anginal
- ACE inhibitors
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- SANOFI-Synthelabo (India) Private Limited
- Gilead Sciences, Inc.
- Amgen, Inc.
- GlaxoSmithKline Plc.
- AstraZeneca Plc.
- Eli Lilly and Company
- Pfizer, Inc.
- Novartis International AG
- XyloCor Therapeutics, Inc.
- Tasly Pharmaceuticals, Inc.
Competitive Landscape
Key players competing in the global angina pectoris drugs market are SANOFI-Synthelabo (India) Private Limited.; Gilead Sciences, Inc.; Amgen, Inc.; GlaxoSmithKline Plc.; AstraZeneca Plc.; Eli Lilly and Company; Pfizer, Inc.; Novartis International AG; XyloCor Therapeutics, Inc.; and Tasly Pharmaceuticals, Inc.
The main market players are continuously engaged in the activities such as mergers, acquisitions, research and developments, investments for innovative products, and collaborations to strengthen their products portfolio and consumer base.
Request For Customization
Enquiry Before Buying
Speak With Analyst
